CCL5

AACR 2023 | ImmVira presented preclinical study results of first CAR-T enabler oncolytic product MVR-T7011 at AACR Annual Meeting

Retrieved on: 
Wednesday, April 19, 2023

SHENZHEN, China, April 17, 2023 /PRNewswire/ -- On April 18, 2023, U.S. time, ImmVira presented preclinical study results of CAR-T enabler oHSV product MVR-7011 through poster publication at the American Association for Cancer Research ("AACR") annual meeting.

Key Points: 
  • SHENZHEN, China, April 17, 2023 /PRNewswire/ -- On April 18, 2023, U.S. time, ImmVira presented preclinical study results of CAR-T enabler oHSV product MVR-7011 through poster publication at the American Association for Cancer Research ("AACR") annual meeting.
  • A breakthrough advantage is that current CAR-T therapies originally targeting blood cancer can be enabled on solid tumors without any modifications required.
  • At the AACR meeting, ImmVira presented the main preclinical study results of MVR-T7011 for the first time.
  • ImmVira has completed in-house pilot-scale manufacturing of MVR-T7011 and launched preclinical study.

City of Hope scientists develop new potential treatment for brain tumors

Retrieved on: 
Tuesday, November 29, 2022

LOS ANGELES, Nov. 29, 2022 /PRNewswire/ -- Glioblastoma multiforme (GBM), the most common type of brain cancer, is notoriously difficult to treat. Its tumor cells mutate rapidly, pushing into deep areas of the brain that can be difficult to reach with surgery and other treatments. GBMs are also able to turn off the mechanism that typically brings immune cells to a damaged area of the body, so that immunotherapies don't work against the disease.

Key Points: 
  • Scientists with City of Hope, one of the largest cancer research and treatment organizations in the United States, have developed a new approach to attract immune cells to brain tumors.
  • To overcome those challenges, scientists with City of Hope, one of the largest cancer research and treatment organizations in the United States, have developed a new approach to attract immune cells to these tumors.
  • The immune cells have to cross through the blood brain barrier to get to the brain.
  • For more information about City of Hope, follow us on Facebook , Twitter , YouTube , Instagram and LinkedIn .

AIM ImmunoTech Announces Positive Data from Phase 1 Study Evaluating Ampligen® for the Treatment of Stage 4 Metastatic Triple Negative Breast Cancer

Retrieved on: 
Monday, April 11, 2022

OCALA, Fla., April 11, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced the presentation of positive data from a Phase 1 study at Roswell Park Comprehensive Cancer Center in patients with metastatic triple-negative breast cancer using chemokine modulation therapy, including AIM ImmunoTech Inc.’s drug candidate, Ampligen® (also known as rintatolimod), interferonα-2b, and pembrolizumab at the American Association for Cancer Research (AACR) Annual Meeting 2022, being held April 8-13, 2022, in New Orleans, Louisiana.

Key Points: 
  • In the study, six evaluable patients (33-75 years) with mTNBC received 6 doses of Ampligen (200 mg i.v.
  • Three patients had stable disease lasting 2.4, 2.5 and 3.8 months, as of data cut off September 1, 2021.
  • An additional patient (non-evaluable) had a partial response (breast tumor autoamputation) with massive tumor necrosis in the post-CKM biopsy.
  • Significant additional testing and trials will be required to determine whether Ampligen will be an effective treatment of Stage 4 metastatic triple negative breast cancer or otherwise, and no assurance can be given that this will be the case.

AIM ImmunoTech Announces Abstract Entitled, Negative Impact of Paclitaxel on Human Breast Tumor Microenvironment and Its Reversal by the Combination of Interferon-α with TLR3 Agonist Rintatolimod, (Ampligen®), Accepted for Poster Presentation by Roswell

Retrieved on: 
Thursday, March 24, 2022

Our current data highlight thepotential for the chemokine modulatory regimen to enhance the effectiveness of taxane-based chemotherapy of breast cancer and potentially other diseases.

Key Points: 
  • Our current data highlight thepotential for the chemokine modulatory regimen to enhance the effectiveness of taxane-based chemotherapy of breast cancer and potentially other diseases.
  • Unexpectedly, paclitaxel treatment resulted in further elevation of granulocyte/MDSC-attractant CXCL8 and CCL22, which was reversed by the combination of paclitaxel with the CKM including Ampligen.
  • Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the PSLRA.
  • The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

ImmVira's New-Generation Vector Poised to Enable CAR-T Treatment for Solid Tumors

Retrieved on: 
Tuesday, January 25, 2022

With MVR-T7, extracellular domains of aforementioned biomarkers can be continuously and precisely expressed on the cell membranes of solid tumors after customized oHSV entering into tumor site, providing targets for CAR-T treatment.

Key Points: 
  • With MVR-T7, extracellular domains of aforementioned biomarkers can be continuously and precisely expressed on the cell membranes of solid tumors after customized oHSV entering into tumor site, providing targets for CAR-T treatment.
  • The design principle of MVR-T7 series is to use oHSV as vector to safely deliver biomarkers that have demonstrated success in CAR-T treatment of hematologic malignancies and make these biomarkers viable in solid tumors.
  • In addition, oncolysis caused by oHSV turn dense solid tumor tissues soft and loose, allowing CAR-T penetration into solid tumor stroma.
  • The elegant design is a breakthrough to achieve maximum treatment benefit for CAR-T therapy on solid tumors.

ORION BIOTECHNOLOGY RECEIVES FUNDING TO ADVANCE ITS LEAD GPCR-TARGETED THERAPEUTIC

Retrieved on: 
Thursday, November 4, 2021

The funding will support the development of Orions lead compound, OB-002, a GPCR analog of CCL5 with best-in-class potency and broad applicability across a range of serious diseases including cancer and neuroinflammation.

Key Points: 
  • The funding will support the development of Orions lead compound, OB-002, a GPCR analog of CCL5 with best-in-class potency and broad applicability across a range of serious diseases including cancer and neuroinflammation.
  • We are very pleased to receive advisory services and this funding from NRC IRAP, said Mark Groper, President and CEO of Orion Biotechnology.
  • Their support will help accelerate development of OB-002 as a potentially important therapy for the treatment of serious illnesses.
  • Orions lead candidate, OB-002, is a first-in-class Chemokine Analog and best-in-class CCR5 antagonist.

Caris Life Sciences to Present New Data at ESMO 2021 Highlighting Gene Expression in Colorectal Cancer - Comprehensive Profiling and Clinical Value

Retrieved on: 
Wednesday, September 15, 2021

Here we analyzed data from a large clinic-molecular database at Caris Life Sciences, and report a strong association of CCR5/CCL5 gene expression with distinct molecular features, as well as with treatment benefit in colon cancer," said Heinz-Josef Lenz, M.D., FACP.

Key Points: 
  • Here we analyzed data from a large clinic-molecular database at Caris Life Sciences, and report a strong association of CCR5/CCL5 gene expression with distinct molecular features, as well as with treatment benefit in colon cancer," said Heinz-Josef Lenz, M.D., FACP.
  • The full results will be presented during a poster display session as part of the ESMO Virtual Congress 2021.
  • The title of the poster is (Presentation Number: 454P), "CCR5/CCL5 Gene Expression in Colorectal Cancer: Comprehensive Profiling and Clinical Value."
  • Caris will present additional data from studies demonstrating the critical role of precision medicine and molecular profiling in driving treatment decisions for people with clear-cell renal cell carcinoma and prostate cancer.

Orion Biotechnology Receives Funding to Test OB-002 for Treatment of COVID-19

Retrieved on: 
Thursday, July 30, 2020

OB-002 is the first of a new class of drugs, called Chemokine Analogs, being developed by Orion Biotechnology leveraging its proprietary Drug Discovery Platform.

Key Points: 
  • OB-002 is the first of a new class of drugs, called Chemokine Analogs, being developed by Orion Biotechnology leveraging its proprietary Drug Discovery Platform.
  • CCL5 (RANTES) is an inflammatory chemokine which has been shown to play an important role in the development of ARDS.
  • We are delighted to receive advisory services and funding from NRC IRAP, which will contribute to further innovative research towards ending the COVID-19 global pandemic, stated Mark Groper, President and CEO of Orion Biotechnology.
  • Ross MacLeod Orion Biotechnology Canada Ltd. +1 343.291.1032 [email protected]

IncellDx Files Patent for CCL5/RANTES Utility as a Diagnostic, Prognostic, and Therapeutic Biomarker in COVID-19 and Other Cytokine Storm Conditions

Retrieved on: 
Thursday, June 18, 2020

IncellDx announces the patent filing with the USPTO and the Pre-EUA with the FDA for CCL5/RANTES Utility as a Diagnostic, Prognostic, and Therapeutic Biomarker in COVID-19.

Key Points: 
  • IncellDx announces the patent filing with the USPTO and the Pre-EUA with the FDA for CCL5/RANTES Utility as a Diagnostic, Prognostic, and Therapeutic Biomarker in COVID-19.
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of a novel coronavirus disease 2019 (COVID-19), is now a global pandemic.
  • Other Cytokines included in the COVID-19 Cytokine Panel can be used to monitor other COVID-19 therapeutic approaches targeting other cytokines involved in the cytokine storm.
  • Company files Pre-EUA with FDA for CCR5 receptor occupancy and a COVID cytokine panel including IL-6, IL-8,TNF-a, GM-CSF, and CCL5/RANTES.